Shares of Mednax, Inc (NYSE:MD) have received a consensus rating of “Hold” from the fifteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $62.38.

A number of equities analysts have commented on MD shares. Zacks Investment Research raised Mednax from a “sell” rating to a “hold” rating in a report on Thursday, April 27th. Bank of America Corporation cut Mednax from a “buy” rating to an “underperform” rating in a report on Thursday, May 4th. BidaskClub raised Mednax from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Stephens raised Mednax from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $55.00 to $68.00 in a report on Thursday, June 22nd. Finally, TheStreet cut Mednax from a “b-” rating to a “c+” rating in a report on Tuesday, May 16th.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/11/mednax-inc-nysemd-receives-consensus-recommendation-of-hold-from-analysts.html.

Mednax (MD) traded up 1.54% during mid-day trading on Friday, reaching $42.75. The company’s stock had a trading volume of 459,195 shares. The firm’s 50 day moving average is $54.64 and its 200-day moving average is $61.63. Mednax has a 12-month low of $41.52 and a 12-month high of $72.13. The company has a market cap of $3.94 billion, a PE ratio of 13.61 and a beta of 0.40.

Mednax (NYSE:MD) last announced its earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. During the same quarter in the prior year, the firm earned $1.03 earnings per share. The business’s revenue was up 9.2% compared to the same quarter last year. Equities analysts anticipate that Mednax will post $3.31 earnings per share for the current fiscal year.

In related news, insider Joseph M. Calabro sold 23,327 shares of the stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total value of $1,282,985.00. Following the completion of the transaction, the insider now directly owns 296,379 shares in the company, valued at $16,300,845. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total value of $113,355.33. Following the completion of the transaction, the director now owns 18,072 shares of the company’s stock, valued at $1,040,405.04. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. raised its position in shares of Mednax by 8.1% in the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock valued at $117,000 after buying an additional 145 shares during the last quarter. Ledyard National Bank raised its position in shares of Mednax by 19.0% in the first quarter. Ledyard National Bank now owns 1,725 shares of the company’s stock valued at $120,000 after buying an additional 275 shares during the last quarter. Commonwealth Bank of Australia raised its position in shares of Mednax by 15.3% in the second quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock valued at $132,000 after buying an additional 293 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Mednax by 870.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,000 shares of the company’s stock valued at $139,000 after buying an additional 1,794 shares during the last quarter. Finally, Morgan Dempsey Capital Management LLC raised its position in shares of Mednax by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock valued at $157,000 after buying an additional 78 shares during the last quarter.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.